Liminatus Pharma raises $650K in private placement, a small sum even for preclinical biotech

What's the deal? Liminatus PharmaDealroom has a profile for this one. Try Dealroom → sold 260,001 common shares at $2.50 each to a single non-US investor, raising gross proceeds of $650,002.50. The company disclosed the private placement in an 8-K filing on November 3, 2026, under a subscription agreement dated November 2.

How small is it? The raise ranks in roughly the 11th percentile by size among comparable deals — a modest financing even for a preclinical biotech. Liminatus plans to use net proceeds for working capital and general corporate purposes.

The details: The shares were issued under Section 4(a)(2) of the Securities Act, Rule 506(b) of Regulation D, and/or Regulation S. Liminatus agreed to file a resale registration statement within 60 days of closing, which is expected on or about November 20, 2026. Chief executive officer Chris Kim signed the filing.

Why it matters: The placement adds incremental liquidity rather than a material standalone round. Liminatus reported $3.0 million in cash at June 30, against roughly $4 million in trailing operating cash outflow.

Context: The deal follows larger equity financings, including a $4 million public offering in February 2026. Notably, the $2.50 price sits well above that offering's $0.29 price, though the two had different terms, including warrants.

The signal: For a cash-burning preclinical biotech, even small placements count as runway. The US$545't move the needle far against Liminatus's spending, pointing to ongoing pressure to keep raising.

Read more: kalkine.com

Image credit: Generated with Gemini